1st Quarter - Report
GEPHARDT GROUP GOVERNMENT AFFAIRS for HEALIANCE PHARMACEUTICALS
Client
Income
$50,000
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
innovative diabetes treatment
Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JANICE O'CONNELL | — |
Pharmacy PHA
innovative diabetes treatment
Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JANICE O'CONNELL | — |
Foreign Relations FOR
innovative diabetes treatment
Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JANICE O'CONNELL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.